Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients

To join the main part of this study, you would need to be at least 18 years old and have an advanced type of non-small cell lung cancer (NSCLC) that has an ALK gene change. Your cancer also needs to have started growing again after having received at least one other type of ALK inhibitor drug.

You would also need to be well enough to take part, as assessed by your doctor, and have cancer that can be measured on scans. Before starting, doctors would need to confirm that your cancer cells have the ALK gene change, usually through past tests like FISH or IHC.

There's also an optional part of the study for people who are currently doing well on a second-generation ALK inhibitor. For this, you would need to have been on your current ALK inhibitor for at least 6 months (if you previously took crizotinib) or 12 months (if crizotinib was not your first ALK inhibitor).

The detailed involvement in this study isn't fully described in the summary, but typically, taking part in a clinical trial involves a series of hospital visits. These visits will likely include regular check-ups with the study team, blood tests to monitor your health and look for genetic changes, and imaging scans (like CT or MRI) to see how the cancer is responding to treatment. You would be taking lorlatinib medication as part of the study. There would be an initial screening phase to ensure you meet all the criteria, followed by regular treatment and assessment periods. After treatment, there would usually be a follow-up period to monitor your long-term health. The total duration of participation varies depending on individual response and the study's design.